Cell Reports (Dec 2016)

Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis

  • J. Travis Hinson,
  • Anant Chopra,
  • Andre Lowe,
  • Calvin C. Sheng,
  • Rajat M. Gupta,
  • Rajarajan Kuppusamy,
  • John O'Sullivan,
  • Glenn Rowe,
  • Hiroko Wakimoto,
  • Joshua Gorham,
  • Kehan Zhang,
  • Kiran Musunuru,
  • Robert E. Gerszten,
  • Sean M. Wu,
  • Christopher S. Chen,
  • Jonathan G. Seidman,
  • Christine E. Seidman

DOI
https://doi.org/10.1016/j.celrep.2016.11.066
Journal volume & issue
Vol. 17, no. 12
pp. 3292 – 3304

Abstract

Read online

AMP-activated protein kinase (AMPK) is a metabolic enzyme that can be activated by nutrient stress or genetic mutations. Missense mutations in the regulatory subunit, PRKAG2, activate AMPK and cause left ventricular hypertrophy, glycogen accumulation, and ventricular pre-excitation. Using human iPS cell models combined with three-dimensional cardiac microtissues, we show that activating PRKAG2 mutations increase microtissue twitch force by enhancing myocyte survival. Integrating RNA sequencing with metabolomics, PRKAG2 mutations that activate AMPK remodeled global metabolism by regulating RNA transcripts to favor glycogen storage and oxidative metabolism instead of glycolysis. As in patients with PRKAG2 cardiomyopathy, iPS cell and mouse models are protected from cardiac fibrosis, and we define a crosstalk between AMPK and post-transcriptional regulation of TGFβ isoform signaling that has implications in fibrotic forms of cardiomyopathy. Our results establish critical connections among metabolic sensing, myocyte survival, and TGFβ signaling.

Keywords